Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis

Stopped early · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis

In brief

The purpose of this study is to evaluate the safety and tolerability of ATA188 as a monotherapy in Parts 1 and 2, to determine the recommended Part 2 dose (RP2D) of ATA188 as monotherapy in Part 1, and to evaluate the effect of ATA188 treatment on clinical disability, as assessed by confirmed Expanded Disability Status Scale (EDSS) improvement at 12 months in Part 2 in participants with progressive forms of multiple sclerosis (MS) (primary progressive multiple sclerosis \[PPMS\] and secondary progressive multiple sclerosis \[SPMS\]).

Key facts

Study ID

NCT03283826

Run by

Atara Biotherapeutics

People needed

134

Starts

2017-10-19

Expected to finish

2024-01-17

Last updated by the study team

2024-02-23

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• For Part 1: History of progressive forms of MS (PPMS or SPMS), as defined by the 2010 Revised McDonald criteria for the diagnosis of MS
• For Part 1: 18 to < 66 years of age
• For Part 1: EDSS scores of 3.0 to 7.0. Participants with EDSS scores of 6.5 to 7.0 must retain measurable upper limb function as assessed by the 9-hole Peg Test (9HPT).
• For Part 2: Current diagnosis of a progressive form of MS (PPMS or SPMS) as defined by the 2017 Revised McDonald criteria
• For Part 2:18 to < 61 years of age
• For Part 2:EDSS scores of 3.0 to 6.5
• Positive EBV serology
• Willing and able to provide written informed consent

You may not qualify if…

• Clinical relapse as follows: For Part 1: Active clinical relapse between providing informed consent and the first dose of study drug. For Part 2: Documented clinical and/or radiological relapse for 2 years prior to screening, including gadolinium (Gd)-enhancing lesion(s) on any brain MRI scans available during this period (A participant will also be considered ineligible if any clinical and/or radiological relapse is reported between screening and the first dose of study drug.)
• Concurrent serious uncontrolled or unresolved medical condition, such as infection, limiting protocol compliance or exposing the subject to unacceptable risk
• Positive serology and/or nucleic acid testing (NAT) for human immunodeficiency virus (HIV), active hepatitis B virus (HBV) infection or carrier status for HBV, active hepatitis C virus (HCV) infection
• For Part 1: Positive serology for syphilis or human T cell lymphotrophic virus I/II
• Uncontrolled psychosis, uncontrolled depression or suicide risk, substance dependence, or any other psychiatric condition that may compromise the ability to participate in this trial
• Clinically significant abnormalities of full blood count, renal function, or hepatic function
• Any contraindication to MRI and/or Gd, eg., any object that is reactive to strong static magnetic, pulsed-gradient fields including any metallic fragments or foreign body (eg, aneurysm clip[s], pacemakers, electronic implants, shunts)
• Any history of cancer (as exceptions, successfully treated non-melanoma skin cancer or carcinoma in situ of the cervix with a < 5% chance of recurrence within 12 months of providing informed consent are allowed.)
• Prior therapy with corticosteroids (within 2 weeks before Cycle 1 Day 1)
• Prior therapy (30 days) B-cell depleting agent (eg, anti-CD20 agents such as ocrelizumab); participant must be progressing despite therapy to be eligible
• For Part 1: Prior therapy (6 half-lives or 30 days whichever is longer) with cladribine, glatiramer acetate, interferon β, dimethyl fumarate, methotrexate, azathioprine, cyclosporine, fingolimod, natalizumab, teriflunomide, mitoxantrone, cyclophosphamide, any other immunosuppressant or cytotoxic therapy (other than steroids), antithymocyte globulin or similar anti-T-cell antibody therapy, or any other investigational product
• For Part 1: Any previous treatment with alemtuzumab, ablative stem cell transplant, or EBV T-cell therapy
• For Part 2: Prior therapy (6 half-lives or 30 days whichever is longer) with IV immunoglobin, plasmapheresis, Bruton's tyrosine kinase inhibitors, all sphingosine 1-phosphate receptor modulators (eg, fingolimod), glatiramer acetate, interferon β, nuclear factor (erythroid-derived 2)-like 2 (Nrf2) activators (eg, dimethyl fumarate), methotrexate, azathioprine, cyclosporine, natalizumab, teriflunomide, mitoxantrone, cyclophosphamide, any other immunosuppressant or cytotoxic therapy (other than steroids), antithymocyte globulin or similar anti-T-cell antibody therapy, or any other investigational product
• For Part 2: Any previous treatment with cladribine, alemtuzumab, ablative stem cell transplant, or EBV T-cell therapy
• Unresolved reactions from previous therapies that may, in the investigator's opinion, impact the safety of the participant or the conduct of this study
• Unwilling to use protocol specified contraceptive methods
• Women who are breastfeeding
• Pregnancy
• Inability or unwillingness to comply with study procedures

Where it is running

• University of California, San Diego — La Jolla, California, United States
• Kaiser Permanente MS Clinic Los Angeles — Los Angeles, California, United States
• Stanford University — Palo Alto, California, United States
• University of California San Francisco — San Francisco, California, United States
• University of Colorado — Aurora, Colorado, United States
• Advanced Neurology — Fort Collins, Colorado, United States
• Neurology Associates, PA-Maitland — Maitland, Florida, United States
• University of South Florida, Morsani College of Medicine — Tampa, Florida, United States
• Fort Wayne Neurological Center — Fort Wayne, Indiana, United States
• University of Kansas Medical Center KUMC - Multiple Sclerosis MS Center — Kansas City, Kansas, United States
• Ochsner Clinic Foundation — New Orleans, Louisiana, United States
• Dragonfly Research — Wellesley, Massachusetts, United States
• Washington University in St. Louis — St Louis, Missouri, United States
• Dent Neurologic Institute — Amherst, New York, United States
• Columbia University Medical Center-The Neurological Institute of New York — New York, New York, United States
• University of Rochester Medical Center - URMC — Rochester, New York, United States
• PMG Research of Piedmont Healthcare — Mooresville, North Carolina, United States
• University of Pennsylvania — Philadelphia, Pennsylvania, United States
• Premier Neurology P.C. — Greer, South Carolina, United States
• Advanced Neurosciences Institute ANI - Franklin — Franklin, Tennessee, United States
• Vanderbilt Comprehensive Multiple Sclerosis Center — Nashville, Tennessee, United States
• The University of Texas Health Science Center at Houston — Houston, Texas, United States
• MS Center of Greater Washington — Vienna, Virginia, United States
• Inland Northwest Research LLC — Spokane, Washington, United States
• Medical College of Wisconsin — Milwaukee, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.